Arrowhead Pharmaceuticals (NASDAQ:ARWR) Rating Reiterated by HC Wainwright

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Friday, Marketbeat Ratings reports. They presently have a $60.00 price objective on the biotechnology company’s stock, down from their previous price objective of $90.00. HC Wainwright’s price target would indicate a potential upside of 139.33% from the stock’s current price.

A number of other research firms have also weighed in on ARWR. The Goldman Sachs Group began coverage on shares of Arrowhead Pharmaceuticals in a report on Wednesday, June 5th. They set a “neutral” rating and a $31.00 target price on the stock. Chardan Capital restated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, June 26th. Morgan Stanley lowered their target price on shares of Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating on the stock in a research note on Monday, May 13th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a research note on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Thursday, June 20th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $44.56.

Arrowhead Pharmaceuticals Trading Down 0.6 %

ARWR stock opened at $25.07 on Friday. Arrowhead Pharmaceuticals has a 1-year low of $20.67 and a 1-year high of $39.83. The stock has a market cap of $3.11 billion, a P/E ratio of -5.90 and a beta of 0.94. The stock’s fifty day simple moving average is $24.59 and its two-hundred day simple moving average is $28.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. The firm’s quarterly revenue was down 100.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.45 EPS. As a group, analysts forecast that Arrowhead Pharmaceuticals will post -3.05 earnings per share for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider Tracie Oliver sold 9,394 shares of the company’s stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total transaction of $237,480.32. Following the completion of the transaction, the insider now owns 127,107 shares of the company’s stock, valued at approximately $3,213,264.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Victoria Vakiener sold 1,799 shares of the business’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $23.31, for a total transaction of $41,934.69. Following the transaction, the director now owns 30,205 shares in the company, valued at $704,078.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Tracie Oliver sold 9,394 shares of the stock in a transaction that occurred on Tuesday, July 2nd. The stock was sold at an average price of $25.28, for a total value of $237,480.32. Following the completion of the transaction, the insider now directly owns 127,107 shares of the company’s stock, valued at approximately $3,213,264.96. The disclosure for this sale can be found here. 4.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in ARWR. Van ECK Associates Corp grew its position in shares of Arrowhead Pharmaceuticals by 22.9% in the 4th quarter. Van ECK Associates Corp now owns 2,395 shares of the biotechnology company’s stock worth $73,000 after buying an additional 447 shares during the period. Washington Trust Advisors Inc. purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth about $25,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Arrowhead Pharmaceuticals by 12.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 8,714 shares of the biotechnology company’s stock valued at $279,000 after purchasing an additional 952 shares in the last quarter. Securian Asset Management Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 12.5% during the first quarter. Securian Asset Management Inc. now owns 10,100 shares of the biotechnology company’s stock valued at $289,000 after purchasing an additional 1,121 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $41,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.